ImageneBio (IMA) Net Cash Flow (2020 - 2025)
ImageneBio (IMA) posted Net Cash Flow of -$64.0 million for Q3 2025, down 344.85% sequentially from $26.1 million in Q2 2025, and down 192.98% YoY from $68.8 million in Q3 2024.
ImageneBio (IMA) Net Cash Flow (2020 - 2025) Analysis & Trends
ImageneBio has reported Net Cash Flow for 6 years, with the latest figure at -$64.0 million in Q3 2025.
- Quarterly Net Cash Flow fell 192.98% year-over-year to -$64.0 million in Q3 2025, while the trailing twelve-month figure through Dec 2025 was -$45.0 million (up 44.32% YoY) and the FY2024 annual result came in at -$80.9 million, down 233.99% from the prior year.
- Net Cash Flow retreated to -$64.0 million in Q3 2025 per IMA's latest filing, from $26.1 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $118.5 million in Q1 2021 and troughed at -$185.3 million in Q1 2022.
- A 5-year average of -$10.8 million and a median of -$7.2 million in 2025 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2021 and 2024: Net Cash Flow soared 1288.76% in 2021, then sank 5256.69% in 2024.
- Over 5 years, Net Cash Flow stood at -$13.7 million in 2021, then soared by 47.71% to -$7.2 million in 2022, then soared by 80.67% to -$1.4 million in 2023, then tumbled by 5256.69% to -$74.1 million in 2024, then advanced by 13.65% to -$64.0 million in 2025.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$64.0 million, $26.1 million, and -$7.2 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -496,000.00 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -37.14 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 225.59 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -2.83 Bn |
| 10 | ImageneBio | 48.60 Mn | -86.75 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -63.97 Mn |
| Sep 30, 2025 | -63.97 Mn |
| Jun 30, 2025 | 26.13 Mn |
| Jun 30, 2025 | 26.13 Mn |
| Mar 31, 2025 | -7.20 Mn |
| Mar 31, 2025 | -7.20 Mn |
| Dec 31, 2024 | -74.08 Mn |
| Dec 31, 2024 | -74.08 Mn |
| Sep 30, 2024 | 68.80 Mn |
| Sep 30, 2024 | 68.80 Mn |
| Jun 30, 2024 | -8.58 Mn |
| Jun 30, 2024 | -8.58 Mn |
| Mar 31, 2024 | -67.04 Mn |
| Mar 31, 2024 | -67.04 Mn |
| Dec 31, 2023 | -1.38 Mn |
| Dec 31, 2023 | -1.38 Mn |
| Sep 30, 2023 | 50.82 Mn |
| Sep 30, 2023 | 50.82 Mn |
| Jun 30, 2023 | 4.54 Mn |
| Jun 30, 2023 | 4.54 Mn |